Physiomics PLC Change in role of board Director
January 13 2023 - 1:00AM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
13 January 2023
13 January 2023
Physiomics plc
("Physiomics") or ("the Company")
Change in role of board director
Physiomics plc (AIM: PYC), the consultancy using mathematical
models to support the development of drug treatment regimens and
personalised medicine solutions, announces that Dr Christophe
Chassagnole's job title has changed from Chief Operating Officer to
Chief Scientific Officer. This title aligns more closely with Dr
Chassagnole's current role and responsibilities and the expectation
that, going forward, he will spend more time focused on the
Company's personalised medicines initiatives. The change builds on
the ongoing restructuring of the board which commenced last year
with the hiring of two highly experienced Non-Executive
Directors.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 90 projects, involving over 40 targets and
70 drugs, and has worked with clients such as Merck KGaA, Astellas,
Merck & Co and Bicycle Therapeutics.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABRGDBXGBDGXD
(END) Dow Jones Newswires
January 13, 2023 02:00 ET (07:00 GMT)
Physiomics (LSE:PYC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From Jul 2023 to Jul 2024